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A new reversed-phase High Performance Liquid Chromatography (HPLC) 
PHWKRG ZDV GHYHORSHG DQG YDOLGDWHG IRU WKH GHWHUPLQDWLRQ RI ¿URFR[LE LQ
equine tissue. Firocoxib was detected by ultraviolet detection at 290nm 
after undergoing a liquid extraction using ethyl acetate: hexane (40:60) and 
VHSDUDWLRQRQD6XQ¿UH&FROXPQ7KHPRELOHSKDVHFRQVLVWHGRIZDWHUZLWK
WULÀXRURDFHWLFDFLGDQGDFHWRQLWULOHZLWKDÀRZUDWHP/PLQ
$FRQFHQWUDWLRQ UDQJHRIQJJPSURGXFHGD OLQHDUFXUYHZLWK U!
7KHORZHUOLPLWRITXDQWL¿FDWLRQZDVQJJP7KHLQWUDDQGLQWHUDVVD\YDULDELOLW\
was <10% and the average recovery was 97%. 
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Introduction
Firocoxib, 3-(cyclopropylmethoxy)-4-(4-(methyl-sulfonyl) 
phenyl)-5, 5-dimethylfuranone, is a coxib-class Non-Steroidal Anti-
In!ammatory Drug (NSAID) approved for use in horses and dogs 
[1]. It is a Cyclo-Oxygenase (COX) inhibitor that is highly speci"c 
for COX-2 and has little e#ect on COX-1 enzymes. Cyclo-oxygenase 
plays an important role in the production of prostaglandins and 
thromboxanes [1]. $e inhibition of COX blocks prostaglandin 
synthesis and prostaglandin-mediated e#ects including in!ammation.
Placentitis is well established as a signi"cant cause of pregnancy 
loss in mares. In a study looking at 1800 mares during a 24-year period 
it was found that 64% of the pregnancy losses were due to placentitis 
[2]. Data in horses support the addition of an anti-in!ammatory 
agent to the antimicrobial therapy for prevention of preterm delivery 
a%er placental infection [3]. $e speci"city of "rocoxib for COX-2 
inhibition, and its potential anti-in!ammatory e#ects, has made it a 
desirable drug for the treatment of placentitis. To validate the use of 
"rocoxib in mares with placentitis, it is critical to determine if the 
drug attains therapeutic concentrations in target tissues.
$ere are methods for detecting "rocoxib in plasma, urine and 
milk [1,4-8]. However, a literature search revealed no published 
methods for the determination of "rocoxib in tissue. A simple and 
reliable method to determine the concentration of "rocoxib in 
equine tissue has been developed in the Pharmacology laboratory 
at the University of Tennessee using a liquid extraction technique, 
ultraviolet detection, and reverse phase HPLC. 
Materials and Methods
Equipment
$e chromatography system consisted of a 2695 separation 
module and a 2487 ultraviolet detector (Waters, Milford, MA). 
Empower so%ware (Waters) was used for data acquisition and 
processing. Firocoxib separation was achieved on a Waters Sun"re 
C18 (4.6mm x 150 mm, 3.5 µm) column preceded by a 3.5µm Sun"re 
C18 guard column (20 mm x 3.9 mm).
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Chromatographic conditions
$e mobile phase was an isocratic mixture of water with 0.025% 
tri!uoroacetic acid and acetonitrile (50:50, v/v). All solutions were 
"ltered through a 0.22 µm "lter and degassed before their use. $e 
!ow rate was 1.1 mL/min, and the column temperature was ambient 
(22oC).Ultraviolet detection occurred at 290 nm. 
Preparation of standard solutions
Firocoxib was a gi% from Merial (Duluth, GA). Deracoxib, the 
internal standard, was a gi% from Novartis (East Hanover, NJ). All 
reagent grade chemicals and solvents were purchased from Fisher 
Scienti"c (Pittsburg, PA). Water was obtained from a Barnstead 
Nanopure In"nity (Dubuque, IA) ultrapure water system. Firocoxib 
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produce stock concentrations of 100 µg/mL. Dilutions of "rocoxib 
were prepared in methanol to produce 10, 1 and 0.1 µg/mL working 
stock solutions. Standards were aliquoted into 2-mL vials to prevent 
evaporation and cross contamination. All solutions were protected 
from light in bottles wrapped in aluminum foil and stored at 4oC. By 
comparing standard areas over time, it was determined that they were 
stable for a minimum of 6 months. 
Sample preparation
Previously frozen equine tissue was thawed then 0.5 gm weighed 
and placed into Potter-Elvehjem glass homogenizers with a PTFE 
pestle. Fi%een microliters of internal standard was added (deracoxib, 
100 µg/mL) followed by 5 mL of ethyl acetate: hexane (40:60). $e 
tissue was ground by hand for 3 min. $e tissue and extraction solution 
were transferred to a 15mL glass screw top tube. $e homogenizer 
tube and probe were rinsed with 1mL of extraction solution and the 
rinse added to the screw top tube. $e tubes were vortexed for 60 
seconds then centrifuged for 20 minutes at 1000xg. $e supernatant 
was removed to a clean 16x100 glass tube and evaporated under a 
stream of nitrogen. $ey were re-dissolved in 300 µL of mobile phase 
(50:50), loaded into HPLC vials, and 50 µL were injected into the 
HPLC system.
Preparation of calibration standards
For preparation of calibration standards and quality control 
samples, appropriate volumes of stock solutions were added to 
untreated tissue. $e "nal concentrations for our tissue calibration 
standard curve were 5, 10, 25, 50, 100, 250, 500, 1000, and 1500 ng/
gm with quality control standards of 7.5, 175, 750, and 1250 ng/gm. 
Calibration standards and control samples were treated the same as 
test samples (Figure 1).
Method validation
Speci!city: For speci"city testing, untreated cervical star and 
amnion tissue were prepared in the same manner as study samples.
Linearity: $e tissue peak ratio (area of "rocoxib divided by 
the internal standard area) versus the concentration was plotted 
and linearity assessed by linear regression analysis. $e calibration 
curve had to have a correlation coe&cient of 0.99 or better. $e 
acceptance criterion for each back-calculated standard concentration 
was 15% deviation from the nominal value except Lower Limit of 
Quanti"cation (LLOQ), which was set at 20%. 
Precision and accuracy: Five replicates of quality control 
standards at concentrations of 7.5, 175, 750, and 1250 ng/gm were 
used to determine the precision and accuracy of this assay. Figure 2:&KURPDWRJUDPVIRU¿URFR[LE$EODQNFHUYLFDOVWDUWLVVXH
Figure 2:%QJJPVSLNHGFHUYLFDOVWDUWLVVXHVWDQGDUG
Figure 2: (C) cervical star tissue sample from a horse after oral administration 
RIPJNJ¿URFR[LE
Figure 2:'EODQNDPQLRQWLVVXH
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Results and Discussion
For speci"city testing, six di#erent blank cervical star tissue 
samples were used in the pre-validation process. Endogenous tissue 
components did not interfere with elution of the compounds of 
interest. Figure 2 shows chromatograms of (A) a blank cervical star, 
(B) a 7.5 ng/gm spiked tissue standard and (C) a cervical star tissue 
sample from a horse a%er oral administration of 0.1 mg/kg "rocoxib. 
$e retention times for "rocoxib and deracoxib were 6.31 and 7.12 
minutes, respectively.
$e tissue area ratio versus the concentration produced a linear 
curve for the concentration used (5-1500 ng/gm) with resulting 
correlation coe&cients of >0.99. A typical equation for the calibration 
curve was y = 0013x + 0.0122, where y represents the peak area 
ratios of "rocoxib to internal standard and x represents the tissue 
concentration of "rocoxib in nanograms per gram. $e intra and 
inter-assay Coe&cient of Variation (CV) for tissue spiked with 
speci"c concentrations of "rocoxib was used to determine accuracy 
and precision which ranged from 2.3-10%. A typical dose response 
curve for cervical star tissue is illustrated in Figure 3. $e precision 
was below the set ± 15% for all quality control samples as shown in 
Table 1 and Table 2.
Figure 2:(QJJPVSLNHGDPQLRQWLVVXHVDPSOH
Figure 2:  (F) an amnion tissue sample from a horse after oral administration 
RIPJNJ¿URFR[LE
$e recovery (Table 2) of "rocoxib from spiked tissue was 
determined by comparing the extracted areas with the directly 
injected analytes areas and ranged from 96% to 98%. $e relative 
standard deviation was less than 10% for all values. $e recovery of 
deracoxib was 95% and its relative standard deviation was 8.9%. $e 
use of deracoxib as an internal standard corrects for intra- and inter-
day assay variability in the assay. $e Lower Limit of Quanti"cation 
(LLOQ) was 5 ng/gm, which represents a peak approximately "ve 
times baseline noise.
Testing of short term stability of the quality control standards 
indicated there was no loss of drug a%er 24 hours in the auto sampler 
and no loss a%er 24 hours in the refrigerator at 4oC. $erefore, if there 
were a power or equipment failure, samples could be reanalyzed. 
A%er storage at -80oC for 30 days, there was less than 1% drug loss 
for the same quality control standards. $is is two weeks longer than 
study samples were stored for analysis. Samples in our studies were 
thawed one time and analyzed; however, there was no loss of drug 
a%er two freeze-thaw cycles.
$is method was also validated in amnion tissue. $e 
chromatograms of (D) a blank amnion tissue, a (E) 175 ng/gm spiked 
Figure 3:'RVHUHVSRQVHFXUYH IRUFHUYLFDOVWDU WLVVXH IRUWL¿HGZLWKTXDOLW\
control concentrations.







(mean ± S.D.) R.S.D. (%)
7.5 6.7± 0.26 3.9
175  
750 733 ± 26 3.5
1250 1255 ± 29 2.3
Assay linearity (n = 5)
Mean ± S.D. R.S.D. (%)
Y-Intercept 0.0122  ± 0.0002 1.4
Slope 0.0013 ± 0.00009 7.4
r2  0.07
SD: Standard Deviation; n: number of samples; RSD: Relative Standard Deviation
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amnion tissue sample, and (F) an amnion tissue sample from a horse 
a%er oral administration of 0.1 mg/kg "rocoxib are illustrated in 
Figure 2. $e same number of blank amnion tissues were used for 
speci"city testing as for the cervical star tissue and no endogenous 
components from this tissue were found to interfere with the elution 
of "rocoxib or deracoxib. $e retention times were 6.30 and 7.12 
for "rocoxib and deracoxib, respectively. A typical equation for this 
calibration curve was y = 0.0013x + 0.0036 with an r2 of 0.999. $e 
intra-assay coe&cient of variation ranged from 1.4% to 6.2% while 
the inter-assay variation ranged from 0.9% to 8.7%. $e recovery of 
"rocoxib ranged from 94% to 102% while the average recovery of the 
internal standard was 95% ± 7%. $e LOD and LLOQ were the same 
in the amnion tissue as the cervical star.
$ere are no other tissue methods in the literature to compare the 
one developed here but there are a few that have analyzed "rocoxib 
in plasma [1,4,7] and milk [8]. Our lower limit of quanti"cation 
(5 ng/gm) is better than the UV method of Kavaternick et al. [1], 
which is 25 ng/ml, and is the same as Hovanessian et al. [4] however; 
methods using mass spectrometry do have lower values (1 and 2 ng/
ml) than our method. $e analysis time for our method is shorter 
than the methods of Kavaternick et al. [1] and Hovanessian et al. 
[4] but slightly longer than the mass spectrometry methods. Mass 
spectrometry is expensive and not always available in all laboratories. 
If a lower limit of quanti"cation is necessary the injection volume 
could be increased and if a shorter run time is needed then the mobile 
phase could be adjusted. Some potential factors that could impact 
sample analysis would include sample matrix, the condition of the 






R.S.D. (%) Recovery (%)
7.5 6.2 ± 0.64 10.0 
175 179 ± 13 7.3 97
750 712 ± 54 7.6 96
1250 1251 ± 56 4.5 97
Table 2:,QWHUDVVD\YDULDELOLW\DQGUHFRYHU\IRU¿URFR[LELQFHUYLFDOVWDUWLVVXH
and (n = 5).
SD: Standard Deviation; n: number of days; RSD: Relative Standard Deviation
treated samples which could lead to the production of interfering 
peaks. $e concurrent administration of other drugs may also impact 
study results. Any drugs that were going to be administered should be 
checked for interfere with the assay.
Conclusion
$is method is capable of quantifying "rocoxib consistently and 
reliably in equine tissues. $e procedure has been authenticated in 
terms of recovery, linearity, LLOQ, precision, and accuracy. Our 
results indicate that the HPLC method is reproducible and provides 
consistent quanti"cation of "rocoxib in tissue. $is method has been 
successfully used to determine "rocoxib concentrations in tissue 
samples analyzed at this institution (Table 3). $e development of 
this method will allow investigators to determine if "rocoxib reaches 
therapeutic concentrations in target tissues making it a potential 
candidate for the treatment of placentitis in horses. To our knowledge 
this is the "rst method developed to analyze "rocoxib in tissues.
References
1. .YDWHUQLFN 9 0DOLQVNL 7 :RUWPDQQ - )LVFKHU - 4XDQWLWDWLYH +3/&89
PHWKRG IRU WKH GHWHUPLQDWLRQ RI ¿URFR[LE IURP KRUVH DQG GRJ SODVPD -
&KURPDWRJU%$QDO\W7HFKQRO%LRPHG/LIH6FL
2. Hong CB, Donahue JM, Giles RC Jr, Petrites-Murphy MB, Poonacha KB, 
Roberts AW, et al. Etiology and pathology of equine placentitis. J Vet Diagn 
Invest. 1993; 5: 56-63.
3. Bailey CS, Heitzman JM, Buchanan CN, Bare CA, Sper RB, Borst LB, et 
al. B-mode and Doppler ultrasonography in pony mares with experimentally 
LQGXFHGDVFHQGLQJSODFHQWLWLV(TXLQH9HW-6XSSO
4. Hovanessian N, Davis JL, McKenzie HC 3rd, Hodgson JL, Hodgson DR, 
&ULVPDQ093KDUPDFRNLQHWLFVDQGVDIHW\RI¿URFR[LEDIWHURUDODGPLQLVWUDWLRQ






performance liquid chromatography. J Chromatogr B Analyt Technol Biomed 
/LIH6FL
7. /HWHQGUH / .YDWHUQLFN 9 7HFOH % )LVFKHU - $XWRPDWHG OLTXLG
chromatography-tandem mass spectrometry method for the analysis of 
¿URFR[LE LQXULQHDQGSODVPD IURPKRUVHDQGGRJ -&KURPDWRJU%$QDO\W
7HFKQRO%LRPHG/LIH6FL








Citation: Cox S, Hayes J, Gordon K, White M and Macpherson M. A Validated Method for the Determination of 
Firocoxib in Equine Tissues. Austin Chromatogr. 2015; 2(3): 1036.
Austin Chromatogr - Volume 2 Issue 3 - 2015
ISSN 2379-7975 | www.austinpublishinggroup.com 
Cox et al. © All rights are reserved
